Literature DB >> 1464612

Characterization of the human pleiotrophin gene. Promoter region and chromosomal localization.

Y S Li1, R M Hoffman, M M Le Beau, R Espinosa, N A Jenkins, D J Gilbert, N G Copeland, T F Deuel.   

Abstract

The protein (PTN) encoded by the pleiotrophin (PTN) gene belongs to a recently described family of heparin-binding cytokines whose expression is temporally and spatially regulated during development. We have now isolated genomic clones of the human PTN gene, characterized its promoter region, determined its transcription initiation site(s), and established functional activity of the PTN promoter. A fragment -550/+191 that contains a CAAT box, no apparent TATA box, and four consensus sites for the binding of MyoD is sufficient to provide optimal promoter activity. A serum response element is found at -559 to -568. We also have identified the human PTN gene on chromosome 7, band q33 and the mouse Ptn gene on chromosome 6, respectively. The data thus identify and characterize the 5' end of the PTN gene and its promoter region, suggest potential regions that may contribute to the regulation of its transcriptional activity, and localize the PTN gene in human and mouse chromosomes.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1464612

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  16 in total

1.  Chronic myeloid leukemia stem cells require cell-autonomous pleiotrophin signaling.

Authors:  Heather A Himburg; Martina Roos; Tiancheng Fang; Yurun Zhang; Christina M Termini; Lauren Schlussel; Mindy Kim; Amara Pang; Jenny Kan; Liman Zhao; Hyung Suh; Joshua P Sasine; Gopal Sapparapu; Peter M Bowers; Gary Schiller; John P Chute
Journal:  J Clin Invest       Date:  2020-01-02       Impact factor: 14.808

2.  Upregulation of pleiotrophin gene expression in developing microvasculature, macrophages, and astrocytes after acute ischemic brain injury.

Authors:  H J Yeh; Y Y He; J Xu; C Y Hsu; T F Deuel
Journal:  J Neurosci       Date:  1998-05-15       Impact factor: 6.167

3.  Human trophoblast and choriocarcinoma expression of the growth factor pleiotrophin attributable to germ-line insertion of an endogenous retrovirus.

Authors:  A M Schulte; S Lai; A Kurtz; F Czubayko; A T Riegel; A Wellstein
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-10       Impact factor: 11.205

Review 4.  Targeting midkine and pleiotrophin signalling pathways in addiction and neurodegenerative disorders: recent progress and perspectives.

Authors:  G Herradón; C Pérez-García
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

5.  The mouse Spam1 maps to proximal chromosome 6 and is a candidate for the sperm dysfunction in Rb(6.16)24Lub and Rb(6.15)1Ald heterozygotes.

Authors:  X Deng; J Moran; N G Copeland; D J Gilbert; N A Jenkins; P Primakoff; P A Martin-DeLeon
Journal:  Mamm Genome       Date:  1997-02       Impact factor: 2.957

6.  The OMP-lacZ transgene mimics the unusual expression pattern of OR-Z6, a new odorant receptor gene on mouse chromosome 6: implication for locus-dependent gene expression.

Authors:  M Pyrski; Z Xu; E Walters; D J Gilbert; N A Jenkins; N G Copeland; F L Margolis
Journal:  J Neurosci       Date:  2001-07-01       Impact factor: 6.167

Review 7.  Pleiotrophin and peripheral nerve injury.

Authors:  Li Jin; Chen Jianghai; Liu Juan; Kang Hao
Journal:  Neurosurg Rev       Date:  2009-05-08       Impact factor: 3.042

8.  Mapping the midkine family of developmentally regulated signaling molecules.

Authors:  C L Peichel; S W Scherer; L C Tsui; D R Beier; T F Vogt
Journal:  Mamm Genome       Date:  1993-11       Impact factor: 2.957

Review 9.  Molecular and pharmacologic targeting of angiogenesis factors--the example of pleiotrophin.

Authors:  F Czubayko; A M Schulte; S C Missner; S S Hsieh; K J Colley; A Wellstein
Journal:  Breast Cancer Res Treat       Date:  1995       Impact factor: 4.872

Review 10.  The potential role of the heparin-binding growth factor pleiotrophin in breast cancer.

Authors:  A T Riegel; A Wellstein
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.